Blog
RSS FeedPosted by Michael Wonder on 31 Jan 2023
New Zealand Pharmaceutical Schedule - 1 February 2023
1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jan 2023
Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s
22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...
Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for ...
Posted by Michael Wonder on 15 Jan 2023
PHARMAC's year in review leaves much to be desired
1 January 2023 - Christmas came early for a number of long-suffering patients. ...
Posted by Michael Wonder on 19 Dec 2022
PHARMAC funds more treatments for people with inflammatory bowel disease
20 December 2022 - Pharmac has today announced funding of ustekinumab (Stelara) for people with inflammatory bowel disease (IBD) and ...
Posted by Michael Wonder on 19 Dec 2022
Allergy advocate group 'absolutely delighted' after PHARMAC announces full funding for EpiPen auto-injectors
15 December 2022 - Aotearoa's drug buying agency has announced it will fully fund the EpiPen brand of adrenaline auto-injectors ...
Posted by Michael Wonder on 15 Dec 2022
PHARMAC consulting on two new medicines for lung cancer
16 December 2022 - PHARMAC has reached provisional agreements with two different suppliers to fund two medicines to treat New Zealanders ...
Posted by Michael Wonder on 15 Dec 2022
Children, parents protest PHARMAC funding review at Parliament
14 December 2022 - A petition calling on PHARMAC to "fund lifesaving medicines for all New Zealand children" has been ...
Posted by Michael Wonder on 14 Dec 2022
PHARMAC to fund the EpiPen for severe allergies
15 December 2022 - PHARMAC has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto ...
Posted by Michael Wonder on 13 Dec 2022
PHARMAC petition: fear tamariki with cancer won’t have access to lifesaving medicines
13 December 2022 - A petition, that will be delivered tomorrow to Parliament, on behalf of Tamariki with cancer, chronic ...
Posted by Michael Wonder on 11 Dec 2022
Lives will continue to be lost to meningococcal disease as PHARMAC funding for vaccines does not go far enough
8 December 2022 - Meningitis Foundation says PHARMAC must make both the meningococcal B and ACWY vaccines available to all ...
Posted by Michael Wonder on 11 Dec 2022
Miracle medicines: a cancer specialist sends a message to PHARMAC
11 December 2022 - Let's make one thing crystal clear: effective chemotherapeutic drugs make a tremendous difference to survival outcomes ...
Posted by Michael Wonder on 07 Dec 2022
PHARMAC funds more medicines for New Zealanders
8 December 2022 - PHARMAC has today announced decisions to fund two new medicines and widen access to one other. ...
Posted by Michael Wonder on 07 Dec 2022
Migraine Foundation submits application to PHARMAC to fund Emgality
5 December 2022 - Migraine Foundation Aotearoa New Zealand has submitted a consumer application to Pharmac to fund Emgality (galcanezumab) for ...
Posted by Michael Wonder on 06 Dec 2022
PHARMAC and a very curious case of media management
6 December 2022 - PHARMAC’s funding of Trikafta is a huge win for people with cystic fibrosis. But the media management ...